We performed a 5-question survey of 25 oncologists in the US to gauge current prescribing practices for breast cancer treatments.
Number of pages:15
We performed a 5-question survey of 25 oncologists in the US to gauge current prescribing practices for breast cancer treatments. This survey is a follow-up of two previous surveys (available here and here) performed in May 2015 and assesses whether updated clinical trial data presented at the 2015 ASCO Annual Meeting affects physician opinions on selected drugs and drug candidates.
Drugs and drug candidates discussed:
Ibrance (palbociclib), PFE
Afinitor (everolimus), NVS
In the last three months, how many patients did you see in the following subgroups? Please include all patients in each subgroup, including patients not actively receiving treatment (i.e. in follow-up after treatment).
In the last three months, how many of your patients with metastatic or locally advanced, HR+/HER2-breast cancer received the following regimens: [free numerical response for each choice]
Interim data were presented at ASCO last week for the PALOMA3 trial of palbociclib+fulvestrant as second-line treatment for advanced HR+/HER2- BC: mPFS 9.2 months for palbo+fulvestrant and 3.8 months for placebo+fulvestrant. In the next 12 months, how often will you prescribe the following regimens to patients in the following lines of treatment?
How strongly do the following factors affect your palbociclib prescribing practices? 1=factor doesn’t affect my prescribing at all, 4=factor strongly affects my prescribing
The EGFR/HER2 inhibitor neratinib was tested in a Phase 3 trial in Stage 2/3 HER2+ BC: 1 yr neratinib or pbo PO QD after adjuvant treatment w/ 1 yr Herceptin. Invasive DFS are in the table. TEAEs included 40% Gr3 diarrhea; in another trial, loperamide prophylaxis reduced diarrhea to 5%. If neratinib is approved in 2017, how will you prescribe it to early BC patients in the trial population?
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.